Using an established cell based assay to screen for epigenetic modulators, we report the identification of a novel series of hydroxamic acid derivatives which possess activity as HDAC inhibitors selectively inhibiting HDAC6 over HDAC1 and having specific antiproliferative activity on human cancer cells vs. patient matched normal cells. Here, HDAC6 is linked to cancer.